Proteintech announced the acquisition of ChromoTek

▴ Proteintech announced the acquisition of ChromoTek
The merger will enable the two companies to take full advantage of growing industry opportunities and more effectively address industry challenges

Proteintech, the reference standard for antibodies, announced the acquisition of ChromoTek, a manufacturer of single domain camelid antibodies, also known as nanoantibodies.

ChromoTek is the industry leader in nanoantibodies, high-throughput recombinant reagents used in research activities leading to groundbreaking discoveries. The merger will enable the two companies to take full advantage of growing industry opportunities and more effectively address industry challenges in single cell analysis, super resolution imaging and multiplexing assays.

"Our specialized nanoantibody-based tools seamlessly integrate with Proteintech's comprehensive antibody portfolio that covers a large part of the proteome," says Dr Marion Jung, CEO of ChromoTek. "It is exciting to collaborate with a company that shares our values ​​in terms of reproducibility and quality for the benefit of research and beyond," he adds.

Proteintech CEO Dr Jason Li commented: "This new collaboration will generate considerable value for the market. The availability of manufacturing facilities on three different continents will allow us to better meet the needs of the research market and will have a profound impact on translational science and therapeutic applications ".

Founded in 2002, Proteintech is a leading manufacturer of antibodies, proteins and immunoassays. The company has the largest unique portfolio of self-made antibodies that cover two-thirds of the human proteome. With more than 70,000 publications and a proven specificity, Proteintech offers antibodies and immunoassays for all areas of research. Additionally, Proteintech produces cytokines, growth factors, and other human-expressed proteins that are bioactive and meet current GMP standards. 

ChromoTek is a pioneer in the development and commercialization of innovative reagents based on camelid nanoantibodies. Unlike traditional antibodies, nanoantibodies consist of a single polypeptide chain and are the smallest known antibodies. The company has unique expertise in developing nanoantibodies with the desired affinity, specificity, and format for applications in biomedical research areas where other antibody formats do not work. As the market and product leader in high-throughput reagents, we are proud to contribute to groundbreaking research discoveries around the world. 

Tags : #Proteintech #LatestNewsonProteintech22ndOct #ChromoTek #LatestNewsonChromoTek22ndOct #LatestPharmaNews22ndOct #LatestPharmaAcquisitionNews22ndOct #DrMarionJung #DrJasonLi

About the Author

Team Medicircle

Related Stories

Loading Please wait...


Trending Now

Exploring the Link Between Covid-19 Vaccination and Sudden Cardiac Arrests: ICMR StudyNovember 22, 2023
Powering the Future: China's Biodegradable Wireless System for Bioelectronic InnovationNovember 22, 2023
IMS BHU Pioneers Advanced Cardiac Care: Unveiling Cutting-Edge Technologies for Precise DiagnosisNovember 18, 2023
Inito's $6 Million Boost: Transforming Women's Health with AI-Backed Fertility MonitoringNovember 18, 2023
Madras High Court Advocates for Equality: PG Medical Students to Receive Incentive Marks for COVID-19 DutyNovember 18, 2023
Next-Gen Healthcare: CarePods and AI Redefine the Patient ExperienceNovember 17, 2023
Air Quality Crisis: Alarming Rise in Premature Births Linked to Air Quality in Begusarai, BiharNovember 17, 2023
Limerick Contest-2023: A Celebration of Wit and PoetryNovember 17, 2023
IIIT-Hyderabad among top 100 institutions for 5G Use Case LabNovember 17, 2023
Powerful, motivating and inspiring talks marked TEDx Hyderabad Women 2023 which was held with the theme "Two Steps ForwardNovember 17, 2023
Speaking the Diagnosis: How AI in Voice Analysis Is Revolutionizing Diabetes DetectionNovember 17, 2023
FDA Approves Zepbound: A New Medication for Weight Loss by Eli LillyNovember 17, 2023
CoverSelf Raises $8.2 Million in Seed Funding to Revolutionize Healthcare Claims with Innovative Fintech PlatformNovember 16, 2023
From Miracle to Medic: The Extraordinary Journey of India's First Paediatric Liver Transplant RecipientNovember 16, 2023
Combatting Chikungunya: Valneva's Chikungunya Vaccine Cleared by USFDA, Eyes India LaunchNovember 16, 2023
Global Corporate Summit 2023 with the theme Unlocking Opportunities in a Dynamic World heldNovember 16, 2023
2nd IHub-Data Mobility Summit heldNovember 16, 2023
Revolutionary AI-powered technology detects multiple abdominal pathologies simultaneouslyNovember 16, 2023
1 Out of 3 Stroke Patients Suffer Long-Term Health Complications, Says NeurologistNovember 16, 2023
Amrita Hospital, Kochi, Launches App for People with Swallowing DifficultiesNovember 15, 2023